Sugi Predict

Sugi Predict / Compounds / SCHEMBL907182

SCHEMBL907182

SCHEMBL907182

COc1cc2c(Nc3ccc(Cl)c(Cl)c3)ncnc2cc1O

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDR P35968 17/20 0.77
▸ RET P07949 4/20 0.77
▸ KIF5B P33176 3/20 0.77
▸ EPHB4 P54760 8/20 0.66
▸ ERBB2 P04626 5/20 0.66
▸ EGFR P00533 5/20 0.66
▸ JAK3 P52333 2/20 0.66
▸ AURKA O14965 1/20 0.66
▸ INSR P06213 1/20 0.66
▸ FBP1 P09467 1/20 0.66
▸ PDGFRB P09619 1/20 0.66
▸ FLT4 P35916 1/20 0.66
▸ CLK1 P49759 1/20 0.66
▸ TEK Q02763 1/20 0.66
▸ AURKB Q96GD4 1/20 0.66
▸ FLT1 P17948 1/20 0.66
▸ GAK O14976 1/20 0.66
▸ RIPK2 O43353 1/20 0.66
▸ STK10 O94804 1/20 0.66
▸ FLT3 P36888 1/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22630825 0.95 KDR (0.77) KDRRETKIF5BEPHB4ERBB2
Trifluoroacetic Acid SCHEMBL906970 0.91 KDR (0.64) KDRRETKIF5BEPHB4ERBB2
SCHEMBL2100447 0.90 KDR (0.80) KDRRETKIF5BEPHB4ERBB2
SCHEMBL907178 0.90 KDR (0.69) KDRRETKIF5BEPHB4ERBB2
SCHEMBL3238800 0.90 EGFR (0.83) KDRRETKIF5BEPHB4ERBB2
SCHEMBL7870579 0.87 KDR (1.00) KDRRETKIF5BEPHB4ERBB2
SCHEMBL5864546 0.87 KDR (0.82) KDRRETKIF5BEPHB4ERBB2
SCHEMBL20792806 0.86 EGFR (0.87) KDRRETKIF5BEGFRJAK3
Hydrochloric Acid SCHEMBL7867185 0.86 KDR (0.98) KDRRETKIF5BEPHB4ERBB2
SCHEMBL5242610 0.85 KDR (0.81) KDRRETKIF5BEPHB4ERBB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10266518-B2 Solid dosage formulations of substituted quinazoline receptor-type kinase modulators and methods of use thereof SYMPHONY EVOLUTION, INC. (US) 2019-04-23 — — US disclosed
EP-1521747-B1 RECEPTOR-TYPE KINASE MODULATORS AND METHODS OF USE SYMPHONY EVOLUTION INC (US) 2018-09-05 — — EP disclosed
US-20180118724-A1 Receptor-Type Kinase Modulators and Methods of Use SYMPHONY EVOLUTION, INC. (US) 2018-05-03 — — US disclosed
US-9796704-B2 Substituted quinazolines as receptor-type kinase inhibitors SYMPHONY EVOLUTION, INC. (US) 2017-10-24 — — US disclosed
US-9359332-B2 Processes for the preparation of substituted quinazolines SYMPHONY EVOLUTION, INC. (US) 2016-06-07 — — US disclosed
US-20160129032-A1 Receptor-Type Kinase Modulators and Methods of Use SYMPHONY EVOLUTION, INC. (US) 2016-05-12 — — US disclosed
US-9163006-B2 — — 2015-10-20 — — US disclosed
US-20140155418-A1 Receptor-Type Kinase Modulators and Methods of Use SYMPHONY EVOLUTION, INC. (US) 2014-06-05 — — US disclosed
US-8658654-B2 Receptor-type kinase modulators and methods of use SYMPHONY EVOLUTION, INC. (US) 2014-02-25 — — US disclosed
EP-2277867-B1 Compounds, pharmaceutical compositions thereof and their use in treating cancer SYMPHONY EVOLUTION INC (US) 2012-12-05 — — EP disclosed
EP-2277867-B1 Compounds, pharmaceutical compositions thereof and their use in treating cancer SYMPHONY EVOLUTION INC (US) 2012-12-05 — — EP disclosed
EP-2280003-A2 Process for preparing receptor-type kinase modulators Symphony Evolution, Inc. (US) 2011-02-02 — — EP disclosed
EP-2277867-A2 Compounds, pharmaceutical compositions thereof and their use in treating cancer Symphony Evolution, Inc. (US) 2011-01-26 — — EP disclosed
US-20090318373-A1 Receptor-type kinase modulators and methods of use KADMON CORPORATION, LLC 2009-12-24 — — US disclosed
US-7576074-B2 Receptor-type kinase modulators and methods of use KADMON CORPORATION, LLC 2009-08-18 — — US disclosed
EP-1521747-A4 RECEPTOR-TYPE KINASE MODULATORS AND METHODS OF USE EXELIXIS INC (US) 2006-10-11 — — EP disclosed
US-20060069077-A1 Receptor-type kinase modulators and methods of use KADMON CORPORATION, LLC 2006-03-30 — — US disclosed
EP-1521747-A2 RECEPTOR-TYPE KINASE MODULATORS AND METHODS OF USE Exelixis, Inc. (US) 2005-04-13 — — EP disclosed
WO-2004006846-A2 RECEPTOR-TYPE KINASE MODULATORS AND METHODS OF USE EXELIXIS, INC. (US) 2004-01-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060069077-A1 Receptor-type kinase modulators and methods of use EGFR, EPHA2, ERBB4 KDR 17/4885RET 32/4885KIF5B 1694/4885
US-10266518-B2 Solid dosage formulations of substituted quinazoline receptor-type kinase modulators and methods of use thereof EGFR, ERBB4, ERBB3 KDR 16/4885RET 30/4885KIF5B 1724/4885
US-20180118724-A1 Receptor-Type Kinase Modulators and Methods of Use EGFR, EPHA2, ERBB4 KDR 17/4885RET 32/4885KIF5B 1694/4885
US-20090318373-A1 Receptor-type kinase modulators and methods of use EGFR, EPHA2, ERBB4 KDR 17/4885RET 32/4885KIF5B 1694/4885
US-20160129032-A1 Receptor-Type Kinase Modulators and Methods of Use EGFR, EPHA2, ERBB4 KDR 17/4885RET 32/4885KIF5B 1694/4885
US-20140155418-A1 Receptor-Type Kinase Modulators and Methods of Use EGFR, EPHA2, ERBB4 KDR 17/4885RET 32/4885KIF5B 1694/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.